| Literature DB >> 25371800 |
Ghodratollah Roshanaei1, Masoud Sabouri Ghannad2, Mohammad Saatchi3, Salman Khazaei3, Mohammad Mirzaei4.
Abstract
BACKGROUND: At present, limited clinical data is available regarding survival rates of patients co-infected with human immunodeficiency virus (HIV)/tuberculosis (TB) in developing countries.Entities:
Keywords: Complications; Survival Rate; Tuberculosis
Year: 2014 PMID: 25371800 PMCID: PMC4217676 DOI: 10.5812/jjm.10565
Source DB: PubMed Journal: Jundishapur J Microbiol ISSN: 2008-3645 Impact factor: 0.747
The Relationship of Various Factors With Mortality in HIV-TB+ Patients
| Vital Status | P Value | |||
|---|---|---|---|---|
| Survived | Died | Total | ||
|
| 0.02 [ | |||
| Male | 350 (88.8) | 44 (11.2) | 394 (100.0) | |
| Female | 386 (93.5) | 27 (6.5) | 413 (100.0) | |
|
| 0.52 | |||
| Urban | 454 (91.7) | 41 (8.3) | 495 (100.0) | |
| Rural | 282 (90.4) | 30 (9.6) | 312 (100.0) | |
|
| < 0.001 [ | |||
| ≤ 10 | 8 (80.0) | 2 (20.0) | 10 (100.0) | |
| 20-11 | 48 (96.0) | 2 (4.0) | 50 (100.0) | |
| 21-30 | 88 (97.8) | 2 (2.2) | 90 (100.0) | |
| 31-40 | 107 (93.0) | 8 (7.0) | 115 (100.0) | |
| 41-50 | 81 (95.3) | 4 (4.7) | 85 (100.0) | |
| 60-51 | 89 (95.7) | 4 (4.3) | 93 (100.0) | |
| 70-61 | 97 (89.8) | 11 (10.2) | 108 (100.0) | |
| 80-71 | 159 (89.8) | 18 (10.2) | 177 (100.0) | |
| > 81 | 59 (74.7) | 20 (25.3) | 79 (100.0) | |
|
| 0.03 [ | |||
| Pulmonary | 500 (89.8) | 57 (10.2) | 557 (100.0) | |
| Extra pulmonary | 236 (94.4) | 14 (5.6) | 250 (100.0) | |
|
| 0.1 | |||
| Negative | 723 (91.1) | 68 (8.9) | 794 (100.0) | |
| Positive | 10 (100.0) | 3 (0.0) | 13 (100.0) | |
a P value < 0.05 considered as significant.
The Relationship of Various Factors With Mortality in HIV+TB+ Patients [a]
| HIV+TB+ | P Value | |||
|---|---|---|---|---|
| Survived | Died | Total | ||
|
| 0.15 | |||
| Male | 6 (30) | 14 (70) | 20 (100) | |
| Female | 1 (100) | 0 | 1 (100) | |
|
| 1 | |||
| Urban | 6 (33.3) | 12 (66.7) | 20 (100) | |
| Rural | 1 (33.3) | 2 (66.7) | 1 (100) | |
|
| 0.12 | |||
| 21-30 | 0 | 1 (100) | 1 (100) | |
| 31-40 | 7 (46.7) | 8 (53.3) | 15 (100) | |
| 41-50 | 0 | 5 (100) | 5 (100) | |
|
| 0.01 [ | |||
| Single | 5 (71.4) | 2 (28.6) | 7 (100) | |
| Married | 2 (14.3) | 12 (85.7) | 14 (100) | |
|
| 0.53 | |||
| Nongovernmental organizations | 2 (28.6) | 5 (71.4) | 7 (100) | |
| Non employees | 3 (33.3) | 6 (66. 7) | 9 (100) | |
| Labors | 1 (25.0) | 3 (75.0) | 4 (100) | |
| Prisoners | 1 (100) | 0 | 1 (100) | |
|
| 1 | |||
| Negative | 3 (33.3) | 6 (66.7) | 9 (100) | |
| Positive | 4 (33.3) | 8 (66.7) | 12 (100) | |
|
| 0.15 | |||
| Non-AIDS [ | 3 (60) | 2 (40) | 5 (100) | |
| AIDS | 4 (25) | 12 (75) | 16 (100) | |
|
| 0.35 | |||
| Negative | 3 (25) | 9 (75) | 12 (100) | |
| Positive | 4 (55.6) | 5 (54.4) | 9 (100) | |
a Abbreviations: HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; TB, tuberculosis.
b P value < 0.05 considered as significant.
c From stage one to stage three.